GENE ONLINE|News &
Opinion
Blog

Verve Therapeutics
Partnerships Liver Disease
Verve and Vertex Agree to Co-Develop In Vivo Gene Editing Program for Liver Disease
2022-07-21
Go Prime NASDAQ
Top 10 Biotech IPOs on NASDAQ in 2021
2022-01-19
IPO Heart Disease
Verve Makes Successful Wall Street Debut on Back of its Promising Base Editor
2021-06-20
JPM Healthcare Conference Highlights: Editas Upbeat about EDIT-101 Success, Verve Continues to Tackle Cholesterol
2021-01-15
In-Depth Cas9
Verve Therapeutic’s One Time Base Editing Treatment Cuts Down Cholesterol Levels in Blood
2020-06-30
LATEST
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
READ MORE
EVENT
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top